This suggests that DR5 can not only be used as an independent indicator for evaluating the prognosis of HCC but also as an effective supplement for judging the prognosis of AFP-negative HCC patients (accounting for 30% in total). The gene discussed is AFP; the disease is hepatocellular carcinoma.